Breast cancer liquid biopsy market growth drivers, analysis

image 1

Breast cancer liquid biopsy is a process of detecting tumor cells in a liquid blood sample drawn from the suspected malignant site. Breast cancer liquid biopsy is an alternative to surgical biopsy procedures that enables doctors and surgeons to diagnose and treat breast cancer early while also collecting tumor information from blood samples. 

The breast cancer liquid biopsy market size in 2021 was $ 124.46 million, and by 2030 it will reach $604.71 million with a CAGR of 19.2% 2021-2030.

 The World Cancer Research Fund International stated that, in 2020, there were more than 2.26 million new breast cancer cases in women. Factors such as early menarche before age 12, late natural menopause after age 55, and first pregnancy over 30 are associated with the increased risk of breast cancer in women.

Growth drivers of breast cancer liquid biopsy market

Factors contributing to the market’s growth are increasing incidence of breast cancer, use of liquid biopsy instruments, technological innovations in breast cancer, increasing preference for noninvasive procedures, and rising patient awareness towards minimally invasive breast cancer liquid biopsy measures. As per research by Centres for Disease Control and Prevention, by 2050, female breast cancer is predicted to witness an increase in cases by 52%. According to a report by GLOBOCAN, out of all deaths caused due to cancer, breast cancer accounted for 7% of deaths in 2020. 

Other factors, such as the growing funding for R&D in breast liquid biopsy, initiatives taken by government and health organizations, and a rise in breast cancer liquid biopsy

reagent approvals are contributing to the market’s growth.

Market Restraints

Lack of accessibility, awareness regarding breast cancer in underdeveloped countries, lack of skilled professionals, and instances of late-stage diagnosis are the factors hampering the market’s overall growth.

Market opportunities

Growing preference for noninvasive procedures to provide lucrative growth opportunity 

During the forecast period, the primary factors propelling the growth of the breast cancer liquid biopsy market are the general trend toward people’s preferences for various noninvasive healthcare services, whether treatments or diagnosis. The adoption and availability of personalized medicine have also never been easier thanks to the development of liquid biopsy, and the growing trend of developing customized treatments will support the market’s overall expansion during the forecast period.

Market segmentation

  • On the basis of indicators, the industry is segmented into Circulating Tumour Cells, Circulating Cell-free DNA, Extracellular Vesicles, and Other Circulating Biomarkers.

The Circulating Cell-free DNA (cfDNA) Segment is expected to account for a major portion of the market. Circulating tumor cells (CTCs) and cell-free DNA (cfDNA) have been recognized as potential blood-based biomarkers that can provide prognostic and predictive information in cancer over the last decade. The ability to detect emerging genomic alterations linked to drug resistance, the capacity to clarify cancer prognosis and diagnose cancer recurrence or progression, and the potential to monitor tumor molecular profiling in real-time at multiple time points are the factors attributed to the growth of this segment.

  • Based on end-user, the breast cancer liquid biopsy market is segmented into hospitals, physician laboratories, reference laboratories, research institutes, public health laboratories, pathology laboratories, and small molecular laboratories. 

On the basis of end-user, the largest global breast cancer liquid biopsy market is the Reference Laboratories segment. A “Reference laboratory,” as defined by Medicare, is a lab that receives a sample from another lab and runs one or more tests. 

Reference Laboratories are the leading segment because they charge low, they can carry out difficult procedures, and they can perform high-volume routine and specialty testing.

  • On the basis of region, the breast cancer liquid biopsy market is segmented into Asia-Pacific, Europe, South America, North America, the Middle East, and Africa.

North America is likely to have a considerable market share. The reasons are driven by the rising incidence of breast cancer in this region, growing demand for noninvasive therapy, advanced diagnostic techniques, and better health infrastructure.

According to the National Breast Cancer Foundation of America, 62% of breast cancer cases in 2019 were diagnosed at a localized stage. In the United States, female breast cancer accounted for approximately 15.2% of all new cancer cases.

While breast cancer survival rates in North America exceed 80%, they can fall below 40% in some low-income countries, according to the National Cancer Institute. This disparity between countries is largely due to the absence of early detection programs in LMICs.

The market in the Asia Pacific is likely to grow the fastest during the forecast period due to an increase in government schemes to advance healthcare infrastructure and the rising incidence of cancer.

Major players

  • Johnson & Johnson
  • BioceptInc
  • Epic Sciences
  • F. Hoffmann-La Roche Ltd
  • Bio-Rad Laboratories
  • Others

Leave a Reply

Your email address will not be published.